REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

SLU Researcher Finds Help for Alzheimer's-Associated Agitation

Rexulti On Track To Add Claim For Alzheimer's Dementia Agitation

Antipsychotic Drug Reduces Alzheimer's-Associated Agitation

US FDA approves Rexulti as first drug for agitation in Alzheimer's

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA

Decision on Brexpiprazole for Alzheimer's Agitation Due in May

Lundbeck and Otsuka await important exam results on Friday for

Bioxcel shares plunge on FDA warning letter despite promising data

FDA approves first drug to treat agitation linked with Alzheimer's

Why REXULTI® (brexpiprazole) agitation that may happen with

FDA Approves First-Ever Drug for Agitation Associated with

FDA AdCom votes in favour of Lundbeck's/Otsuka's Rexulti in AAD

JAMA Neurology Publishes Complete Results of Positive Phase 3